series-a
Stage
2018
Founded
1
Investors
About
Pheast Therapeutics is a clinical-stage biotechnology company focused on developing macrophage-directed immunotherapies for cancer. Their lead candidate, PHST001, is an anti-CD24 monoclonal antibody designed to block a key immune checkpoint and enhance macrophage-mediated tumor clearance.
Explore Pheast Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.